Search Results
Your search for The ASCO ,The ASCO matches 20581 pages
Showing 5101 - 5150Antiviral T Cells for BK Virus–Associated Hemorrhagic Cystitis
A phase II trial has found found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis, a painful complication that is common after allogeneic stem cell transplants for patients with leukemia or lymphoma. ...
More From the FDA ODAC: Votes on Agents for Pretreated Hepatocellular Carcinoma and Gastric Cancer
More news has emerged from this week’s meeting of the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC). The group voted 8 to 0 in favor of continuing the accelerated approval for pembrolizumab in sorafenib-pretreated patients with hepatocellular carcinoma; 6 to 2...
Fertility Concerns May Influence Decisions About Endocrine Therapy in Young Women With Breast Cancer
Concerns about fertility often influence how young women with breast cancer approach treatment decisions and are a reason for forgoing or delaying hormone-blocking therapy, according to findings from a recent study published by Sella et al in the journal Cancer. The findings reinforce the need for...
Factors Associated With Unplanned Hospitalizations Among Older Patients Receiving Chemotherapy
In a study reported in JCO Oncology Practice, Klepin et al identified several factors associated with unplanned hospitalizations and hospital length of stay among patients with cancer aged 65 and older receiving chemotherapy. Study Details The study was a secondary analysis in a U.S. multisite...
FDA ODAC Votes in Favor of Retaining Accelerated Approval for Bladder Cancer Treatments
Roche has announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favor of maintaining the accelerated approval of atezolizumab for the treatment of adults with locally advanced or metastatic urothelial carcinoma who are not eligible for...
Breast Reconstruction Disparities Improved With Medicaid Expansion
Medicaid expansion under the Affordable Care Act was associated with significant increases in breast reconstruction among non-Hispanic Black women, achieving parity at times with non-Hispanic White women, according to a new study presented by Sharon Lum, MD, and colleagues at the American Society...
Low-Risk Breast Cancer Survivors May Experience Long-Term Physical and Psychological Effects
Survivors of low-risk breast cancer may experience wide-ranging and significant physical and psychological symptoms after cancer treatment, according to a new study presented by Jessica Schumacher, PhD, and colleagues at the American Society of Breast Surgeons (ASBrS) Annual Meeting. Researchers...
Cryoablation Emerging as Effective Treatment for Low-Risk Breast Cancers
Nonsurgical breast cancer cryoablation, which destroys tumor cells by exposing them to subfreezing temperatures, is proving to be an effective alternative to surgery for small breast tumors with low-risk features in women older than age 60. These were the early findings from 3-year results of the...
COVID-19 Pandemic Drove Strategic New Breast Cancer Approaches to Avoid Hospitalization
The COVID-19 pandemic rapidly altered breast cancer treatment approaches, with a significant rise in neoadjuvant endocrine therapy for estrogen receptor–positive tumors, enabling immediate evidence-based treatment of women with an extremely common form of breast cancer, while delaying surgery and...
Updated Information on Sotorasib Dose-Comparison Study
Amgen has announced that it agreed with the U.S. Food and Drug Administration's proposed postmarketing requirement to conduct, as part of the ongoing development program, a multicenter randomized clinical trial to compare the safety and efficacy of sotorasib at 960 mg once daily vs a lower daily...
YouTube Videos on Bladder Cancer: Study Focuses on Quality of Content
Social media platforms are valuable tools for educating patients about serious health topics, but they can also spread false and biased information with potentially harmful results, according to recent research published by Stacy Loeb, MD, MSc, and colleagues in European Urology. Researchers...
New Research Finds Few Young Adult Men Have Received the HPV Vaccine
Using data from the 2010–2018 National Health Interview Surveys, Chen et al found that just 16% of men who were 18 to 21 years old had received at least one dose of the human papillomavirus (HPV) vaccine at any age. In comparison, 42% of women in the same age bracket had gotten at least one shot of ...
FDA ODAC Votes in Favor of Maintaining Accelerated Approval of Atezolizumab/Nab-paclitaxel for PD-L1–Positive, Metastatic Triple-Negative Breast Cancer
Roche announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted seven to two in favor of maintaining accelerated approval of atezolizumab in combination with chemotherapy (nanoparticle albumin-bound paclitaxel, or nab-paclitaxel) for the treatment of ...
Chernobyl at 35 Years: An Oncologist’s Perspective
Editor’s note: Dr. Gale is an authority on medical response to nuclear and radiation accidents and participated in rescue efforts at the Chernobyl disaster, as well as at Goiania, Tokaimura, and Fukushima, among other radiation and nuclear accidents. Anyone reading the popular press or even...
FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma
On April 23, the U.S. Food and Drug Administration (FDA) granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta), a CD19-directed antibody and alkylating agent conjugate, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, ...
AACR and The Mark Foundation for Cancer Research Announce New Grants
The American Association for Cancer Research (AACR) and The Mark Foundation for Cancer Research recently announced five grants to support innovative research focused on understanding the influence of a patient’s biology on the genesis, development, treatment, and survivorship of cancer. Each...
AMA Salutes End to Ban on Transgender Americans in the Military
On January 25, 2021, Susan R. Bailey, MD, President of the American Medical Association (AMA), issued the following statement: “The AMA welcomes the President’s decision to reverse the policy that largely barred transgender people from serving in the military, because there is no medically valid...
NCI Statement on Ending Structural Racism in Biomedical Research
On March 2, 2021, the National Cancer Institute (NCI) issued the following statement: As one of the 27 institutes and centers that make up the NIH [National Institutes of Health], the National Cancer Institute stands with [NIH Director] Dr. Francis Collins and the entire NIH in supporting UNITE. “I ...
Turning Confusion Into Clarity: Lessons Learned From Autism Spectrum Disorder
Autism spectrum disorder refers to a group of conditions characterized by difficulty in navigating normal social situations and having all-absorbing repetitive behaviors or stereotyped interests. At the milder end of the spectrum is Asperger’s syndrome, generally confined to people with higher...
Kathy Giusti, MBA; Nancy Pelosi; and Charles L. Sawyers, MD, FAACR, to Receive AACR Distinguished Public Service Awards
The American Association for Cancer Research (AACR) will present Distinguished Public Service Awards to three individuals whose extraordinary work has exemplified the AACR’s mission to prevent and cure all cancers through research, education, communication, collaboration, science policy, advocacy,...
Clinician Recommendations May Pique Patients’ Interest in Complementary and Integrative Therapies
Patients with cancer expressed more interest in complementary and integrative medicine services when these services were recommended by an oncologist or other medical professional or were provided for free in a clinical trial, according to a survey reported in JCO Oncology Practice.1 The survey...
How Interested Are Patients in Integrative Therapies, and How Much Are They Willing to Pay for Them?
The top two barriers to accessing complementary and integrative therapies, according to a survey of 576 patients with cancer and caregivers, were cost, cited by 56%, and a lack of knowledge about the therapies, cited by 52.1%. “Other barriers included a lack of time (29.2%), location of the...
Grateful to Be Alive
Everything about my breast cancer diagnosis, from my presentation to diagnosis, was strange. In the spring of 2006, I was performing my monthly breast self-exam when I felt a hard lump in the upper left quadrant of my left breast. Having lost a good friend to breast cancer 4 years earlier, I was...
Anti-BCMA–Directed CAR T-Cell Gene Therapy in Relapsed or Refractory Myeloma
"The noblest pleasure is the joy of understanding.” —Leonardo da Vinci To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel...
IMF Launches Initiative to Improve Outcomes in Multiple Myeloma Among Black Americans
The International Myeloma Foundation (IMF) has begun a multiyear, multidisciplinary initiative, M-Power Charlotte, which is designed to promote the early diagnosis and treatment of myeloma in the Black community. The IMF is working with Atrium Health Levine Cancer Institute’s Disparities &...
Ethical Considerations Before Launching a Clinical Cancer Trial
Randomized clinical trials are highly regulated initiatives that must comply with multiple requirements while maintaining high epistemic standards, a balance that becomes increasingly difficult as the research questions surrounding immunotherapy and targeted agents become more complex. To shed...
A Physician-Scientist’s Mother, Who Nursed Those With Chronic Diseases, Fueled His Passion for Biomedical Research
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Griffin P. Rodgers, MD, MACP, Director of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH). Dr. Rodgers, a physician-scientist,...
Narjust Duma, MD, Appointed to Dual Role at Dana-Farber Cancer Institute/Harvard Medical School
Narjust Duma, MD, was recently named Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine at Dana-Farber Cancer Institute/Harvard Medical School. In her role at the Cancer Care Equity Program, Dr. Duma will develop strategies to diminish health-care disparities...
Brendon Stiles, MD, Named Chief of Thoracic Surgery & Surgical Oncology at Montefiore and Albert Einstein
Leading cardiothoracic surgeon and researcher Brendon Stiles, MD, has been appointed Chief of the Division of Thoracic Surgery & Surgical Oncology in the Department of Cardiothoracic and Vascular Surgery at Montefiore Health System and Albert Einstein College of Medicine. Dr. Stiles will also...
CancerCare® Appoints Mark D. Peters II, PharmD, as Vice President for New Business Development and Outreach
CancerCare, the leading national nonprofit organization providing free support services to anyone affected by cancer, recently welcomed Mark D. Peters II, PharmD, to its team as Vice President for New Business Development and Outreach. Dr. Peters, who has more than 30 years of clinical and...
Neeraj Agarwal, MD, Named Senior Director of Clinical Research Innovation by Huntsman Cancer Institute
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) announced the appointment of Neeraj Agarwal, MD, physician-scientist at HCI and Professor of Internal Medicine at the U of U, as Senior Director of Clinical Research Innovation. In this role, Dr. Agarwal will oversee critical...
Improvement Programs to Optimize Patient Care for Black Americans With Breast Cancer
Eight oncology practices in eight different U.S. metropolitan areas with high rates of breast cancer disparities between Black and White Americans have been selected to participate in ASCO’s quality programs, including the Quality Oncology Practice Initiative (QOPI®)and Quality Training Program...
Addressing Oncologist Burnout, Emotional Well-Being, and Moral Distress in the Pandemic
JCO Oncology Practice recently published an editorial that examines the intensified burnout oncology practitioners are experiencing due the COVID-19 pandemic and outlines critical interventions to support oncologists now and throughout a long-term recovery.1 The article was written by past,...
New ASCO Guideline Offers Recommendations for Neoadjuvant Breast Cancer Treatment
ASCO has released a new guideline regarding the use of neoadjuvant chemotherapy, endocrine therapy, and targeted therapy in breast cancer.1 “This is the first time ASCO has embarked on a guideline for neoadjuvant therapy,” said Larissa A. Korde, MD, of the National Cancer Institute, and guideline...
Increasing Cervical Cancer Prevention and Care in Nepal
A new JCO Global Oncology special article details the process and results of a Multidisciplinary Cervical Cancer Prevention Course that ASCO volunteers led in Nepal, where cervical cancer remains the most common cancer among women and most patients present with an advanced stage of the disease.1...
Can Brachytherapy for Cervical Cancer Continue After Uterine Perforation?
A study published by Small et al in the journal Brachytherapy found that the common procedure of interstitial or intracavitary radiotherapy may continue safely—potentially without delay or antibiotics—in patients with cervical cancer following uterine perforation. According to the World Health...
FDA Pipeline: Bemarituzumab Granted Breakthrough Therapy Designation for FGFR2b-Overexpressing, HER2-Negative Gastric Cancer
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to bemarituzumab as first-line treatment for patients with fibroblast growth factor receptor 2b (FGFR2b)-overexpressing and HER2-negative metastatic and locally advanced gastric and gastroesophageal adenocarcinoma...
Nivolumab/Ipilimumab Plus Two Cycles of Histology-Based Chemotherapy: Another Option in First-Line Metastatic NSCLC
Introduction of immunotherapy has revealed a paradigm shift in the management of patients with metastatic non–small cell lung cancer (NSCLC) that does not harbor a therapeutically targetable driver mutation. Over the past 5 years, several trials have informed treatment decisions, based on disease...
FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Endometrial Cancer
On April 22, the U.S. Food and Drug Administration (FDA) granted accelerated approval to dostarlimab-gxly (Jemperli) for adult patients with mismatch repair–deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior...
NCCN 2021 Virtual Annual Conference
New recommendations to advance racial equity, ways to mitigate the impacts of the COVID-19 pandemic on cancer care, and ongoing strategies for preventing and controlling human papillomavirus (HPV)-associated cancers led the conversation at the National Comprehensive Cancer Network® (NCCN®) 2021...
Expert Point of View: Lisa Baumann Kreuziger, MD, MS
Lisa Baumann Kreuziger, MD, MS, Associate Professor of Hematology/Oncology at Versiti/Medical College of Wisconsin, Milwaukee, introduced Terry B. Gernsheimer, MD, at the Plenary Session and spoke with The ASCO Post about the results of the study. “The investigators of the A-TREAT trial tested a...
Study Explores Rates of Germline Mutations in Patients With Colorectal Cancer
In a recent study published by Uson Junior et al in Clinical Gastroenterology and Hepatology, researchers found one in six patients with colorectal cancer had an inherited cancer-related genetic mutation, which may be linked to a predisposition to the disease. In addition, the researchers...
Pembrolizumab Monotherapy for Heavily Pretreated Patients With Metastatic Breast Cancer and High Tumor Mutational Burden
Findings from the ASCO-designed phase II Targeted Agent and Profiling Utilization Registry (TAPUR) basket trial, reported in the Journal of Clinical Oncology by Alva et al, indicated that pembrolizumab showed activity in heavily pretreated patients with metastatic breast cancer and high mutational...
Genitourinary Oncology Highlights 2020–2021 Almanac
Landmark changes in the treatment of genitourinary cancers have occurred over the past year, as summarized in this year’s Genitourinary Oncology Almanac from The ASCO Post. Starting with our area of focus, metastatic renal cell carcinoma, the saga continues with two more positive phase III trials...
Immune Checkpoint Inhibitors and Cutaneous Toxicity: Population-Level Analysis
Immune checkpoint inhibitors have transformed treatment for many advanced cancers, but short-term clinical trials and small observational studies have linked the medications with various side effects, most commonly involving the skin. A more comprehensive, population-level analysis now provides a...
Acute Myeloid Leukemia World Awareness Day 2021: April 21
After a great response to Acute Myeloid Leukemia World Awareness Day (AML WAD) in 2020, Know AML looks forward to commemorating AML WAD in 2021. AML WAD will take place on April 21, 2021, with the aim to facilitate and improve knowledge of AML worldwide through collaborative participation. Know AML ...
To Advance Health Equity, Put Real-World Cancer Data to Work
Despite decades of scientific progress against cancer, access to treatment remains highly unequal. Some of the reasons—like institutional racism and poverty—are a reflection of our broader society. Other inequities may go unrecognized but are no less damaging. People with underlying health...
FDA Pipeline: Recent Designations in Urothelial Cancer, Cervical Cancer, Cholangiocarcinoma, and More
Recently, the U.S. Food and Drug Administration (FDA) issued regulatory decisions related to treatments for urothelial cancer, cervical cancer, cholangiocarcinoma, solid tumors, and colorectal cancer. Acceptance of Two Supplemental Biologics License Applications for Enfortumab Vedotin-ejfv in...
